Bisphosphonates in the treatment of skeletal metastases

Pierfranco Conte, Robert Coleman

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of normal bone homeostasis by bone metastases leads to troublesome skeletal complications, such as bone pain, pathologic fractures, hypercalcemia of malignancy, and spinal cord compression. Bisphosphonates are an effective treatment for skeletal complications. These agents act primarily by initiating biochemical processes that ultimately result in apoptosis of osteoclasts, but they also have a number of other antitumor functions (eg, inhibition of angiogenesis). At present, the most widely used bisphosphonates are oral clodronate and intravenous pamidronate and zoledronic acid. Although these agents are effective in reducing skeletal complications, they are associated with varying safety and convenience issues. More recently, the availability of ibandronate as intravenous and oral formulations represents a new alternative for the treatment of metastatic bone disease. Further studies are necessary to establish the comparative benefits of bisphosphonates in metastatic bone disease.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 10
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Bone Diseases
Diphosphonates
pamidronate
zoledronic acid
Neoplasm Metastasis
Biochemical Phenomena
Clodronic Acid
Bone and Bones
Spontaneous Fractures
Spinal Cord Compression
Health Resources
Hypercalcemia
Osteoclasts
Patient Care
Homeostasis
Therapeutics
Apoptosis
Delivery of Health Care
Safety
Pain

ASJC Scopus subject areas

  • Oncology

Cite this

Bisphosphonates in the treatment of skeletal metastases. / Conte, Pierfranco; Coleman, Robert.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 10, 10.2004, p. 59-63.

Research output: Contribution to journalArticle

Conte, Pierfranco ; Coleman, Robert. / Bisphosphonates in the treatment of skeletal metastases. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 10. pp. 59-63.
@article{8948d758b54b4498b826acf601c3e3fd,
title = "Bisphosphonates in the treatment of skeletal metastases",
abstract = "Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of normal bone homeostasis by bone metastases leads to troublesome skeletal complications, such as bone pain, pathologic fractures, hypercalcemia of malignancy, and spinal cord compression. Bisphosphonates are an effective treatment for skeletal complications. These agents act primarily by initiating biochemical processes that ultimately result in apoptosis of osteoclasts, but they also have a number of other antitumor functions (eg, inhibition of angiogenesis). At present, the most widely used bisphosphonates are oral clodronate and intravenous pamidronate and zoledronic acid. Although these agents are effective in reducing skeletal complications, they are associated with varying safety and convenience issues. More recently, the availability of ibandronate as intravenous and oral formulations represents a new alternative for the treatment of metastatic bone disease. Further studies are necessary to establish the comparative benefits of bisphosphonates in metastatic bone disease.",
author = "Pierfranco Conte and Robert Coleman",
year = "2004",
month = "10",
doi = "10.1053/j.seminoncol.2004.07.024",
language = "English",
volume = "31",
pages = "59--63",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 10",

}

TY - JOUR

T1 - Bisphosphonates in the treatment of skeletal metastases

AU - Conte, Pierfranco

AU - Coleman, Robert

PY - 2004/10

Y1 - 2004/10

N2 - Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of normal bone homeostasis by bone metastases leads to troublesome skeletal complications, such as bone pain, pathologic fractures, hypercalcemia of malignancy, and spinal cord compression. Bisphosphonates are an effective treatment for skeletal complications. These agents act primarily by initiating biochemical processes that ultimately result in apoptosis of osteoclasts, but they also have a number of other antitumor functions (eg, inhibition of angiogenesis). At present, the most widely used bisphosphonates are oral clodronate and intravenous pamidronate and zoledronic acid. Although these agents are effective in reducing skeletal complications, they are associated with varying safety and convenience issues. More recently, the availability of ibandronate as intravenous and oral formulations represents a new alternative for the treatment of metastatic bone disease. Further studies are necessary to establish the comparative benefits of bisphosphonates in metastatic bone disease.

AB - Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of normal bone homeostasis by bone metastases leads to troublesome skeletal complications, such as bone pain, pathologic fractures, hypercalcemia of malignancy, and spinal cord compression. Bisphosphonates are an effective treatment for skeletal complications. These agents act primarily by initiating biochemical processes that ultimately result in apoptosis of osteoclasts, but they also have a number of other antitumor functions (eg, inhibition of angiogenesis). At present, the most widely used bisphosphonates are oral clodronate and intravenous pamidronate and zoledronic acid. Although these agents are effective in reducing skeletal complications, they are associated with varying safety and convenience issues. More recently, the availability of ibandronate as intravenous and oral formulations represents a new alternative for the treatment of metastatic bone disease. Further studies are necessary to establish the comparative benefits of bisphosphonates in metastatic bone disease.

UR - http://www.scopus.com/inward/record.url?scp=5644240878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644240878&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.07.024

DO - 10.1053/j.seminoncol.2004.07.024

M3 - Article

C2 - 15490377

AN - SCOPUS:5644240878

VL - 31

SP - 59

EP - 63

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 10

ER -